Solventum (NYSE:SOLV) Price Target Raised to $99.00 at KeyCorp

Solventum (NYSE:SOLV) had its price target upped by KeyCorp from $97.00 to $99.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other research firms have also commented on SOLV. BTIG Research reiterated a “buy” rating and set a $100.00 price objective on shares of Solventum in a research note on Friday. UBS Group reaffirmed a “neutral” rating on shares of Solventum in a research note on Friday, November 21st. Wall Street Zen cut Solventum from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Zacks Research lowered Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Solventum in a research note on Wednesday, December 17th. Seven analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $91.64.

Solventum Stock Performance

Shares of NYSE SOLV traded down $2.82 during midday trading on Friday, reaching $74.12. 2,241,844 shares of the company traded hands, compared to its average volume of 1,105,137. The company has a market cap of $12.86 billion, a price-to-earnings ratio of 8.36, a PEG ratio of 7.10 and a beta of 0.35. The stock has a 50-day moving average price of $78.58 and a 200 day moving average price of $76.20. Solventum has a 52 week low of $60.70 and a 52 week high of $88.20. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14.

Solventum (NYSE:SOLV) last announced its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. The firm had revenue of $2 billion during the quarter, compared to analyst estimates of $1.96 billion. Solventum had a net margin of 18.69% and a return on equity of 26.99%. Solventum’s revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.41 EPS. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Sell-side analysts anticipate that Solventum will post 6.58 earnings per share for the current fiscal year.

Solventum announced that its board has approved a share repurchase plan on Thursday, November 20th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the company to purchase up to 7.5% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.

Institutional Investors Weigh In On Solventum

A number of large investors have recently made changes to their positions in SOLV. Nisa Investment Advisors LLC lifted its stake in Solventum by 0.6% in the 2nd quarter. Nisa Investment Advisors LLC now owns 33,974 shares of the company’s stock worth $2,577,000 after acquiring an additional 210 shares in the last quarter. South Dakota Investment Council increased its holdings in shares of Solventum by 3.6% in the 2nd quarter. South Dakota Investment Council now owns 255,625 shares of the company’s stock valued at $19,387,000 after purchasing an additional 8,960 shares during the period. Purus Wealth Management LLC acquired a new position in shares of Solventum in the 2nd quarter valued at about $252,000. Terril Brothers Inc. lifted its position in shares of Solventum by 15.3% in the second quarter. Terril Brothers Inc. now owns 96,516 shares of the company’s stock worth $7,320,000 after purchasing an additional 12,800 shares in the last quarter. Finally, Jennison Associates LLC purchased a new stake in shares of Solventum in the second quarter worth approximately $3,076,000.

Key Stories Impacting Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q4 beat — SOLV reported $1.57 EPS and $2.0B revenue, topping estimates with strong demand in surgical/wound-care products, supporting the case for continued organic growth. Read More.
• Positive Sentiment: FY2026 guidance nudged above consensus — management set EPS guidance of $6.40–$6.60, slightly ahead of Street expectations, giving some visibility to full‑year earnings. Read More.
• Positive Sentiment: Analyst bullish signals — KeyCorp raised its price target to $99 (overweight) and BTIG reaffirmed a buy with a $100 target, reflecting upside from better-than-expected results and long-term growth potential. Read More. Read More.
• Neutral Sentiment: Full disclosure for investors — the earnings call transcript and slide deck are available for deeper review of segment performance and cost drivers. Read More.
• Negative Sentiment: Margin pressure — several reports and the company’s commentary highlighted declining margins and cost headwinds despite organic sales growth (organic sales +3.5%, overall sales -3.7% y/y), which is the primary driver of investor concern. Read More.
• Negative Sentiment: Analyst caution — Wells Fargo cut its price target to $83 and moved to an equal‑weight stance, signaling shorter-term skepticism that likely amplified selling after the print. Read More.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.